Education

This accredited activity will help clinicians understand the prevalence of TD, recognize the risk factors, and introduce effective screening tools.

This accredited activity explores when to treat TD, and reviews some strategies that are not effective for managing TD and should be avoided.

These accredited videos discuss the role of VMAT2 inhibitors as the preferred treatment for tardive dyskinesia (TD), highlighting their mechanisms of action and differences in metabolism, as well as reviewing practical concerns around use and reviewing FDA-approval status.

View these accredited, narrated videos on deutetrabenazine and valbenazine, providing an overview of their dose-response relationships, highlighting their efficacy in managing tardive dyskinesia, and examining the safety profiles established through clinical studies.